{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT05891080","nct_id":"NCT05891080","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05891080. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"In this arm, 6 patients with resectable or potentially resectable stage III non-small cell lung cancer will receive 4 circles of neoadjuvant toripalimab and JS004 combined with platinum-based doublet chemotherapy and those resectable after neoadjuvant therapy will be treated with surgery.","label":"Safety run-in arm","type":"EXPERIMENTAL"},{"description":"Patients with resectable or potentially resectable stage III non-small cell lung cancer will be randomized into this arm (59 patients) and receive 4 circles of neoadjuvant toripalimab and JS004 combined with platinum-based doublet chemotherapy and those resectable after neoadjuvant therapy will be treated with surgery.","label":"JS004 arm","type":"EXPERIMENTAL"},{"description":"Patients with resectable or potentially resectable stage III non-small cell lung cancer will be randomized into this arm (59 patients) and receive 4 circles of neoadjuvant toripalimab combined with platinum-based doublet chemotherapy and those resectable after neoadjuvant therapy will be treated with surgery.","label":"Control arm","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-07-01","type":"ESTIMATED"},"conditions":["Stage III Non-small Cell Lung Cancer"],"enrollment":{"count":124,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Toripalimab","otherNames":[],"type":"DRUG"},{"name":"JS004","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"},{"name":"Nab-paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Surgery","otherNames":[],"type":"PROCEDURE"}],"last_update":"2023-06-06","lead_sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","official_title":"Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial","overall_status":"NOT_YET_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-07-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Pathologic complete response (PCR) rate","timeFrame":"Up to 30 months"}],"references":[],"start_date":{"date":"2023-07-01","type":"ESTIMATED"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial","url":"https://clinicaltrials.gov/study/NCT05891080"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05891080"}